According to market rumours, AstraZeneca informally approached Gilead for a possible merger last month – if the deal goes ahead, it would be the biggest transaction in pharma industry to date. However, the strategic rationale for the deal appears limited – AstraZeneca and Gilead have limited overlap in businesses and a merger would hardly generate any synergies – and, thus, we believe that this fusion is unlikely. Political interference could also crop up if the rumours are
09 Jun 2020
AstraZeneca Gilead union is hard to digest
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AstraZeneca Gilead union is hard to digest
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
09 Jun 2020 -
Author:
Surbhit Gupta -
Pages:
3
According to market rumours, AstraZeneca informally approached Gilead for a possible merger last month – if the deal goes ahead, it would be the biggest transaction in pharma industry to date. However, the strategic rationale for the deal appears limited – AstraZeneca and Gilead have limited overlap in businesses and a merger would hardly generate any synergies – and, thus, we believe that this fusion is unlikely. Political interference could also crop up if the rumours are